Mp56-13 a prospective randomized controlled trial of transcutaneous electrical nerve stimulation (tens) for the treatment of nocturnal enuresis in children: preliminary results

In children with overactive bladder, neuromodulation using TENS units has yielded modest results compared to posterior tibial (PT) nerve stimulation, which has demonstrated better results. While nocturnal enuresis (NE) does not have a singular cause, presacral neuromodulation has yielded little improvement. We intend to determine whether TENS can be effective in patients with NE when applied to various strategic anatomic locations.
Source: The Journal of Urology - Category: Urology & Nephrology Authors: Tags: Pediatrics: Dysfunctional Voiding & Enuresis Source Type: research

Related Links:

Conclusion: The presence of NE in a third of the patients who developed over time OAB and the earlier onset of OAB for these patients suggests a causal physiopathological relationship between NE and OAB. The preponderance of urban patients confirms the existence of acquired urban triggering factors of OAB (nutritious, social, or professional). PMID: 31203588 [PubMed - as supplied by publisher]
Source: Turkish Journal of Medical Sciences - Category: General Medicine Tags: Turk J Med Sci Source Type: research
Abstract In specialist urology clinics, 50 - 70 % of patients have chronic urological diseases such as recurrent urinary tract infections, a somatoform overactive bladder, adult and infantile enuresis, a chronic pelvic pain syndrome, and the psychosomatic form of post-prostatectomy incontinence. The 12-month prevalence of psychological disorders in the general adult population is 28 % 1. As many as 20 % of children and adolescents are found to have psychological abnormalities 2. These are frequently accompanied by somatoform symptoms, often consisting of a psychosomatic voiding disorder with a consecutiv...
Source: Aktuelle Urologie - Category: Urology & Nephrology Authors: Tags: Aktuelle Urol Source Type: research
ConclusionNocturia is a common condition and very commonly patients have sought treatment prior to presentation. Bladder diaries were recommended to half of the patients. Patient reported that improvement did not seem to correlate with completion of a bladder diary. Though most patients had NP the use of desmopressin was very low. Current treatments used in managing nocturia may lack efficacy.
Source: World Journal of Urology - Category: Urology & Nephrology Source Type: research
DISCUSSION: Transient secondary enuresis is a frequent finding in AT patients, heralding loss of ambulatory capacity, tough it's pathophysiological mechanism is largely no understood. PMID: 30100180 [PubMed - as supplied by publisher]
Source: European Journal of Paediatric Neurology - Category: Neurology Authors: Tags: Eur J Paediatr Neurol Source Type: research
Condition:   Overactive Bladder Interventions:   Drug: Solabegron modified release tablets, low dose;   Drug: Solabegron modified release tablets, high dose;   Drug: Matching Placebo Sponsor:   Velicept Therapeutics, Inc. Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Overactive Bladder Interventions:   Drug: Solabegron modified release tablets, low dose;   Drug: Solabegron modified release tablets, high dose;   Drug: Matching Placebo Sponsor:   Velicept Therapeutics, Inc. Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Overactive Bladder Interventions:   Drug: Solabegron modified release tablets, low dose;   Drug: Solabegron modified release tablets, high dose;   Drug: Matching Placebo Sponsor:   Velicept Therapeutics, Inc. Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Overactive Bladder Interventions:   Drug: Solabegron modified release tablets, low dose;   Drug: Solabegron modified release tablets, high dose;   Drug: Matching Placebo Sponsor:   Velicept Therapeutics, Inc. Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Overactive Bladder Interventions:   Drug: Solabegron modified release tablets, low dose;   Drug: Solabegron modified release tablets, high dose;   Drug: Matching Placebo Sponsor:   Velicept Therapeutics, Inc. Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Overactive Bladder Interventions:   Drug: Solabegron modified release tablets, low dose;   Drug: Solabegron modified release tablets, high dose;   Drug: Matching Placebo Sponsor:   Velicept Therapeutics, Inc. Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Bed Wetting | Brain | Children | Enuresis | Jordan Health | Middle East Health | Neurology | Overactive Bladder | Overactive Bladder Syndrome | Pediatrics | TENS | Urology & Nephrology